Current Report Filing (8-k)
August 03 2020 - 5:20PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13
OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
|
July 31, 2020
|
NANOVIRICIDES, INC.
|
(Exact Name of Registrant as Specified in Its Charter)
|
Nevada
|
001-36081
|
76-0674577
|
(State or Other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
1 Controls Drive,
Shelton, Connecticut 06484
|
06484
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(203) 937-6137
|
(Registrant's Telephone Number, Including Area Code)
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
Common Stock
|
|
NNVC
|
|
NYSE-American
|
Item 1.01
|
Entry into a Material
Definitive Agreement.
|
On
July 31, 2020, NanoViricides, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the
“Sales Agreement”) with B. Riley Securities, Inc. and Kingswood Capital Markets, a division of Benchmark Investments, Inc.
(each a “Sales Agent” and collectively, the “Sales Agents”), pursuant to which the Company may offer and
sell, from time to time, through or to the Sales Agents, shares of the Company’s common stock, par value $0.001 per share
(the “Placement Shares”), having an aggregate offering price of up to $50 million (the “ATM Offering”).
Sales pursuant to the Sales Agreement will be made only upon instructions by the Company to the Sales Agents, and the Company cannot
provide any assurances that it will issue any Shares pursuant to the Sales Agreement.
The
issuance and sale, if any, of the Placement Shares by the Company under the Sales Agreement will be made pursuant to the Company’s
effective “shelf” registration statement on Form S-3 (Registration Statement No. 333-237370) (the “Registration
Statement”), the base prospectus contained therein, and a prospectus supplement relating to the ATM offering, dated July 31,
2020.
Under
the terms of the Sales Agreement, the Company may sell the Placement Shares by any method permitted that is deemed an “at
the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”).
Each Sales Agent will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable
state and federal laws, rules and regulations to sell the Placement Shares from time to time, based upon the Company’s
instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). Actual
sales will depend on a variety of factors to be determined by the Company from time to time, including (among others) market conditions,
the trading price of the Company’s Common Stock, capital needs and determinations by the Company of the appropriate sources
of funding for the Company. The Company is not obligated to make any sales of Common Stock under the Sales Agreement and the Company
cannot provide any assurances that it will issue any shares pursuant to the Sales Agreement. The Company will pay a commission
rate of up to 3.5% of the gross sales price per share sold and agreed to reimburse the Sales Agents for certain specified expenses,
including the fees and disbursements of its legal counsel in an amount not to exceed $50,000 and have agreed to reimburse the Sales
Agents an amount not to exceed $2,500 per quarter during the term of the Sales Agreement for legal fees to be incurred by the Sales
Agents. The Company has also agreed pursuant to the Sales Agreement to provide each Sales Agent with customary indemnification
and contribution rights.
This
Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any security nor shall
there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state.
The
description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text
of the Sales Agreement, a copy of which is included herewith as Exhibit 1.1, and is incorporated herein by reference.
The
opinion of the Company’s counsel regarding the validity of the shares of Common Stock that will be issued pursuant to the
Sales Agreement and the ATM Prospectus Supplement is also filed herewith as Exhibit 5.1.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
Exhibit
Number
|
|
Description
|
|
|
|
1.1
|
|
At Market Issuance Sales Agreement by and between NanoViricides, Inc., B. Riley Securities, Inc. and Kingswood Capital Markets, a division of Benchmark Investments, Inc., dated July 31, 2020
|
|
|
|
5.1
|
|
Opinion of McCarter & English, LLP
|
|
|
|
23.1
|
|
Consent of McCarter & English, LLP (included in Opinion of McCarter & English, LLP filed as Exhibit 5.1)
|
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE
SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO
DULY AUTHORIZED.
|
NANOVIRICIDES, INC.
|
|
|
|
Date: August 3, 2020
|
By:
|
/s/ Anil Diwan
|
|
|
Name: Anil Diwan
|
|
|
Title: Chairman, President
|
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2023 to Sep 2024